Summary
71 / 100 · Bulios Score
What speaks for it
- It earns 23 USD a year on every 100 USD of invested capital.
- The share price is below the Bulios Fair Price.
What to watch
- Revenue growth is slowing: 3.9% a year over the last 3 years against 16% over 5 years.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 15.8 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 16% a year over 5 years. Over the last 3 years it grew by 3.9% a year. Earnings per share grew by 2.4% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 74 USD
- Sales and administration 19 USD
- Taxes and other 2.6 USD
- Net profit 5.1 USD
Net profit, industry median (Conglomerates) 5.5 USD
Out of every 100 USD of revenue, 5.1 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 2
- Hold 1
- Sell 0
No analyst has published a price target.
67% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Health Care 51%
- Engineering Services 38%
- Technology Service 11%
By region
- UNITED STATES 91%
- Europe 4.8%
- CANADA 2.4%
- PUERTO RICO 2.0%
Health Care brings in 51% of revenue.
Segments in detail